A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause

Phase 3

Completed

• Conditions: Vasomotor Symptoms Associated With Menopause; Hot Flashes
• Interventions: Drug: Placebo; Drug: Elinzanetant (BAY3427080)

• Registration Number: NCT05030584
• Lead Sponsor: Bayer

Brief Summary

Researchers are looking for a better way to treat women who have hot flashes after they have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life.

The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people.

In this study, the researchers will learn how well elinzanetant works compared to a placebo in women who have been through the menopause and have hot flashes. A placebo is a treatment that looks like a medicine but does not have any medicine in it. To compare these study treatments, the participants will record information about their hot flashes in an electronic diary. The researchers will study the number of hot flashes the participants have and how severe they are. They will study the results from before treatment and after 12 weeks of treatment.

The participants in this study will take two capsules of either elinzanetant or the placebo once a day. The participants will take the study treatments for 52 weeks.

During the study, the participants will visit their study site approximately 11 times and perform 2 visits by phone. Each participant will be in the study for approximately 62 weeks.

During the study, the participants will:

* record information about their hot flashes in an electronic diary

* answer questions about their symptoms

The doctors will:

* check the participants' health

* take blood samples

* ask the participants questions about what medicines they are taking and if they are having adverse events An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-27
• Study First Submitted: 2021-08-27
• Study First Submitted QC: 2021-08-27
• Study First Posted: 2021-09-01
• Primary Completion: 2023-03-29
• Study Completion: 2024-02-12
• Status Verified: 2024-03
• Disposition First Submitted: 2024-03-13
• Last Update Submitted: 2024-03-13
• Disposition First Posted: 2024-03-15
• Last Update Posted: 2024-03-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 628

Inclusion Criteria

• Postmenopausal, defined as:

  1. at least 12 months of spontaneous amenorrhea prior to signing of informed consent, or
  2. at least 6 months of spontaneous amenorrhea prior to signing of informed consent with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL and a serum estradiol concentration of < 30 pg/mL, or
  3. at least 6 months after hysterectomy at signing of informed consent with serum FSH levels > 40 mIU/mL and a serum estradiol concentration of < 30 pg/mL, or
  4. surgical bilateral oophorectomy with or without hysterectomy at least 6 weeks prior to signing of informed consent.

• Moderate to severe hot flash (HF) associated with the menopause and seeking treatment for this condition.

• Participant has completed Hot Flash Daily Diary (HFDD) for at least 11 days during the two weeks preceding baseline visit and is showing eligibility with respect to previous inclusion criterion during this time period.

Read More

Exclusion Criteria

• Any clinically significant prior or ongoing history of arrhythmias, heart block and QT prolongation either determined through clinical history or on ECG evaluation.

• Any active ongoing condition that could cause difficulty in interpreting vasomotor symptoms (VMS) such as: infection that could cause pyrexia, pheochromocytoma, carcinoid syndrome.

• Current or history (except complete remission for 5 years or more) of any malignancy (except basal and squamous cell skin tumors). Women receiving adjuvant endocrine therapy (e.g. tamoxifen, aromatase inhibitors, GnRH analogues) cannot be enrolled in this study.

• Uncontrolled or treatment-resistant hypertension. Women with mild hypertension can be included in the study if they are medically cleared prior to study participation.

• Untreated hyperthyroidism or hypothyroidism.

  • Treated hyperthyroidism with no abnormal increase of thyroid function laboratory parameters and no relevant clinical signs for > 6 months before signing of informed consent is acceptable.
  • Treated hypothyroidism with normal thyroid function test results during screening and a stable (for ≥ 3 months before signing of informed consent) dose of replacement therapy is acceptable.

• Any unexplained post-menopausal uterine bleeding

• Clinically relevant abnormal findings on mammogram.

• Abnormal liver parameters.

• Disordered proliferative endometrium, endometrial hyperplasia, polyp, or endometrial cancer diagnosed based on endometrial biopsy during screening.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Participants will receive matching placebo orally once daily.
Elinzanetant (BAY3427080)	Elinzanetant (BAY3427080)	Participants will receive 120 mg elinzanetant orally once daily.

Primary Outcome Measures

Name	Time	Method
Mean change in frequency of moderate to severe hot flashes (HFs) from baseline to Week 12 (assessed by hot flash daily diary [HFDD])	Baseline to Week 12

Secondary Outcome Measures

Name	Time	Method
Mean change in patient-reported outcomes measurement information system sleep disturbance short form 8b (PROMIS SD SF 8b) total score over time.	Baseline to Week 56	The PROMIS SD SF 8b includes 8 items assessing sleep disturbance over the past 7 days. Items assess sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Participants respond to the items on a 5-point scale from not at all, never or very poor to very much, always or very good. Four of the items are scored reversely. Total scores range from 8 to 40, with higher scores indicating greater severity of sleep disturbance.
Mean change in menopause specific quality of life scale (MENQOL) total score over time	Baseline to Week 56	The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: Vasomotor functioning, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicates if they have experienced the symptom (yes/no). If they select yes, they rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother.

Trial Locations

Locations (83)

Mesa Obstetricians and Gynecologists; 🇺🇸 Mesa, Arizona, United States

David I Lubetkin, MD, LLC; 🇺🇸 Boca Raton, Florida, United States

HWC Women's Research Center; 🇺🇸 Englewood, Ohio, United States

Mobile Ob-Gyn, PC; 🇺🇸 Mobile, Alabama, United States

Marvel Clinical Research, LLC; 🇺🇸 Huntington Beach, California, United States

Manna Research (Ottawa); 🇨🇦 Nepean, Ontario, Canada

Alpha Recherche Clinique LB9; 🇨🇦 Quebec, Canada

CHU Saint-Pierre/UMC Sint-Pieter; 🇧🇪 Bruxelles - Brussel, Belgium

Viable Clinical Research Corporation; 🇨🇦 Scarborough, Ontario, Canada

Instituto Palacios de Salud y Medicina de la Mujer; 🇪🇸 Madrid, Spain

UZ Gent; 🇧🇪 Gent, Belgium

MC Asklepii OOD; 🇧🇬 Dupnitza, Bulgaria

National Institute of Clinical Research - Garden Grove; 🇺🇸 Garden Grove, California, United States

Sanos Clinic - Syddanmark; 🇩🇰 Vejle, Denmark

Hospital de la Santa Creu i Sant Pau | Gynecology Department; 🇪🇸 Barcelona, Spain

Ottawa Hospital-Riverside Campus; 🇨🇦 Ottawa, Ontario, Canada

Liverpool Womens Hospital; 🇬🇧 Liverpool, United Kingdom

H Univ. Virgen Rocío | Ginecología; 🇪🇸 Sevilla, Spain

Manna Research (Burlington North); 🇨🇦 Burlington, Ontario, Canada

HUS / Naistenklinikka; 🇫🇮 Helsinki, Finland

Mehiläinen Kuopio; 🇫🇮 Kuopio, Finland

MAC Research Centre - Manchester; 🇬🇧 Manchester, United Kingdom

CLINICAL MEDICAL RESEARCH Sp. z o. o.; 🇵🇱 Katowice, Poland

MAC Research Centre Blackpool; 🇬🇧 Blackpool, United Kingdom

Hospital Sanitas La Zarzuela; 🇪🇸 Aravaca, Madrid, Spain

Seattle Clinical Research Center; 🇺🇸 Seattle, Washington, United States

Empire Clinical Research; 🇺🇸 Pomona, California, United States

Coastal Connecticut Research, LLC; 🇺🇸 New London, Connecticut, United States

Office of Dr. James A. Simon, MD; 🇺🇸 Washington, District of Columbia, United States

Helix Biomedics, LLC; 🇺🇸 Boynton Beach, Florida, United States

University of Florida College of Medicine; 🇺🇸 Jacksonville, Florida, United States

Suncoast Clinical Research Center, Inc.; 🇺🇸 New Port Richey, Florida, United States

Suncoast Clinical Research; 🇺🇸 Palm Harbor, Florida, United States

Physician Care Clinical Research; 🇺🇸 Sarasota, Florida, United States

Paramount Research Solutions-College Park; 🇺🇸 College Park, Georgia, United States

Investigators Research Group, LLC; 🇺🇸 Brownsburg, Indiana, United States

Southern Clinical Research Associates LLC; 🇺🇸 Metairie, Louisiana, United States

Johns Hopkins Univ School Med|Johns Hopkins Hosp Dept Gyn/Ob; 🇺🇸 Baltimore, Maryland, United States

Boeson Research - Great Falls OBGYN; 🇺🇸 Great Falls, Montana, United States

Boeson Research - Missoula; 🇺🇸 Missoula, Montana, United States

Wake Research, Inc.; 🇺🇸 Raleigh, North Carolina, United States

Columbus OB-GYN/Radiant Research; 🇺🇸 Columbus, Ohio, United States

Venus Gynecology, LLC former Magnolia OB/GYN Research Center; 🇺🇸 Myrtle Beach, South Carolina, United States

Clinical Research of Philadelphia, LLC; 🇺🇸 Philadelphia, Pennsylvania, United States

UT Health Women's Research Center at Memorial City; 🇺🇸 Houston, Texas, United States

Advances in Health, Inc.; 🇺🇸 Houston, Texas, United States

Women's Health Texas; 🇺🇸 Katy, Texas, United States

Maximos Ob/Gyn; 🇺🇸 League City, Texas, United States

Tidewater Physicians for Women; 🇺🇸 Norfolk, Virginia, United States

Eastern Virginia Medical School | OB/GYN Clinical Research Center; 🇺🇸 Norfolk, Virginia, United States

Sanos Clinic - Nordjylland; 🇩🇰 Gandrup, Denmark

Sanos Clinic - Herlev; 🇩🇰 Herlev, Denmark

Office of Dr. Edmond Pack; 🇺🇸 Las Vegas, Nevada, United States

AMR Las Vegas; 🇺🇸 Las Vegas, Nevada, United States

Las Vegas Clinical Trials, LLC; 🇺🇸 North Las Vegas, Nevada, United States

Glasgow Royal Infirmary | Haematology; 🇬🇧 Glasgow, United Kingdom

Queen Charlottes & Chelseas Hospital; 🇬🇧 London, United Kingdom

H Univ. 12 de Octubre | Ginecología y Obstetricia; 🇪🇸 Madrid, Spain

MHAT for Women's Health - Nadezhda OOD; 🇧🇬 Sofia, Bulgaria

Medical Center Panaceya; 🇧🇬 Sofia, Bulgaria

Twoja Przychodnia - Szczecinskie Centrum Medyczne; 🇵🇱 Szczecin, Poland

Centrum Badawcze Wspolczesnej Terapii; 🇵🇱 Warszawa, Poland

SHOGAT Prof Dimitar Stamatov; 🇧🇬 Varna, Bulgaria

Hospital Clinico Universitario | Gynecology and Obstetrics Department; 🇪🇸 Valencia, Spain

Terveystalo Tampere; 🇫🇮 Tampere, Finland

MHAT Avis Medika; 🇧🇬 Pleven, Bulgaria

Southern Clinical Research, LLC; 🇺🇸 Zachary, Louisiana, United States

Manna Research (Montreal); 🇨🇦 Pointe-Claire, Quebec, Canada

Spec.Hospital for obstetrics and gynecology Selena OOD; 🇧🇬 Plovdiv, Bulgaria

DCC Aleksandrovska; 🇧🇬 Sofia, Bulgaria

MHAT Samokov; 🇧🇬 Samokov, Bulgaria

Multiprofile Hospital for Activ Treatment Plovdiv; 🇧🇬 Plovdiv, Bulgaria

MHAT Niamed; 🇧🇬 Stara Zagora, Bulgaria

Centrum Medyczne Angelius Provita; 🇵🇱 Katowice, Poland

Vita Longa Sp. z o.o.; 🇵🇱 Katowice, Poland

Lääkärikeskus Gyneko; 🇫🇮 Oulu, Finland

CHR de la Citadelle - Department of Gynaecology & Obstetrics; 🇧🇪 Liege, Belgium

Femicare vzw; 🇧🇪 Tienen, Belgium

Spec. Hospital for Active Treatment of Oncological Diseases; 🇧🇬 Sofia, Bulgaria

Manna Research (Quebec); 🇨🇦 Levis, Quebec, Canada

Pihlajalinna Lääkärikeskus Oy, Savo-Karjala; 🇫🇮 Joensuu, Finland

Gabinet Ginekologiczny Janusz Tomaszewski; 🇵🇱 Bialystok, Poland

UZ Leuven Gasthuisberg; 🇧🇪 Leuven, Belgium